Phase I study to evaluate the toxicity and feasibility of intra-tumoral injection of alpha-gal glycosphingolipids [glycosphingolipids] in patients with advanced or refractory solid tumors.

Trial Profile

Phase I study to evaluate the toxicity and feasibility of intra-tumoral injection of alpha-gal glycosphingolipids [glycosphingolipids] in patients with advanced or refractory solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2013

At a glance

  • Drugs AGI 134 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Actual patient number is 11 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top